Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H17N |
Molecular Weight | 151.2487 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC12CC3CC(CC(C3)C1)C2
InChI
InChIKey=DKNWSYNQZKUICI-UHFFFAOYSA-N
InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
Molecular Formula | C10H17N |
Molecular Weight | 151.2487 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Amantadine hydrochloride has pharmacological actions as both an anti-Parkinson and an antiviral drug. The mechanism by which amantadine exerts its antiviral activity is not clearly understood. It appears to mainly prevent the release of infectious viral nucleic acid into the host cell by interfering with the function of the transmembrane domain of the viral M2 protein. In certain cases, amantadine is also known to prevent virus assembly during virus replication. It does not appear to interfere with the immunogenicity of inactivated influenza A virus vaccine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. Data from earlier animal studies suggest that amantadine hydrochloride may have direct and indirect effects on dopamine neurons. More recent studies have demonstrated that amantadine is a weak, non-competitive NMDA receptor antagonist (K1 = 10µM). Although amantadine has not been shown to possess direct anticholinergic activity in animal studies, clinically, it exhibits anticholinergic-like side effects such as dry mouth, urinary retention, and constipation. Amantadine was approved by the FDA in 1966 as a prophylactic agent against Asian influenza, and eventually received approval for the treatment of influenza virus A in adults. In 1969, it was also discovered by accident to help reduce symptoms of Parkinson's disease, drug-induced extrapyramidal syndromes, and akathisia.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15800186 |
10.0 µM [Ki] | ||
Target ID: CHEMBL1932894 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18669647 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MANTADINE HYDROCHLORIDE Approved UseAmantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Launch Date1987 |
|||
Primary | MANTADINE HYDROCHLORIDE Approved UseAmantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Launch Date1987 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
636.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18074029 |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMANTADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.24 μg/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMANTADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6413.6 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18074029 |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMANTADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.7 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18074029 |
100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AMANTADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
AMANTADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.8 g single, oral Overdose Dose: 0.8 g Route: oral Route: single Dose: 0.8 g Sources: Page: p.120 |
healthy, 2 n = 1 Health Status: healthy Age Group: 2 Sex: M Population Size: 1 Sources: Page: p.120 |
Disc. AE: Status epilepticus, Agitation... AEs leading to discontinuation/dose reduction: Status epilepticus Sources: Page: p.120Agitation Diaphoresis Vomiting |
3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: Page: p.757 |
unhealthy, 23 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 23 Sex: M Population Size: 1 Sources: Page: p.757 |
Disc. AE: CNS toxicity... AEs leading to discontinuation/dose reduction: CNS toxicity (grade 5) Sources: Page: p.757 |
10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Co-administed with:: diphenhydramine, p.o(250 mg, single) Sources: Page: p.174 |
unhealthy, 47 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 47 Sex: F Population Size: 1 Sources: Page: p.174 |
Disc. AE: Ventricular tachycardia... AEs leading to discontinuation/dose reduction: Ventricular tachycardia Sources: Page: p.174 |
274 mg 1 times / day multiple, oral Recommended Dose: 274 mg, 1 times / day Route: oral Route: multiple Dose: 274 mg, 1 times / day Sources: Page: p.605 |
unhealthy, 53.3 n = 27 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 53.3 Sex: M+F Population Size: 27 Sources: Page: p.605 |
Disc. AE: Serotonin syndrome, Dry mouth... AEs leading to discontinuation/dose reduction: Serotonin syndrome (serious, 3.7%) Sources: Page: p.605Dry mouth (3.7%) |
274 mg 1 times / day multiple, oral Recommended Dose: 274 mg, 1 times / day Route: oral Route: multiple Dose: 274 mg, 1 times / day Sources: |
unhealthy, 63.9 n = 63 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 63.9 Sex: M+F Population Size: 63 Sources: |
DLT: Visual hallucinations... Disc. AE: Visual hallucinations, Peripheral edema... Dose limiting toxicities: Visual hallucinations (4.8%) AEs leading todiscontinuation/dose reduction: Visual hallucinations (7.9%) Sources: Peripheral edema (4.8%) Dry mouth (4.8%) |
420 mg 1 times / day multiple, oral Highest studied dose Dose: 420 mg, 1 times / day Route: oral Route: multiple Dose: 420 mg, 1 times / day Sources: Page: p.793 |
unhealthy, 66.4 n = 20 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 66.4 Sex: M+F Population Size: 20 Sources: Page: p.793 |
Disc. AE: Hallucinations, Balance disorder... AEs leading to discontinuation/dose reduction: Hallucinations (15%) Sources: Page: p.793Balance disorder (5%) Confusional state (5%) Dry mouth (5%) Subdural hematoma (5%) Constipation (5%) |
100 mg 3 times / day steady, oral Dose: 100 mg, 3 times / day Route: oral Route: steady Dose: 100 mg, 3 times / day Sources: |
unhealthy n = 36 Health Status: unhealthy Condition: Parkinson's disease Population Size: 36 Sources: |
Other AEs: Dry mouth... Other AEs: Dry mouth (below serious, 4 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | Disc. AE | 0.8 g single, oral Overdose Dose: 0.8 g Route: oral Route: single Dose: 0.8 g Sources: Page: p.120 |
healthy, 2 n = 1 Health Status: healthy Age Group: 2 Sex: M Population Size: 1 Sources: Page: p.120 |
Diaphoresis | Disc. AE | 0.8 g single, oral Overdose Dose: 0.8 g Route: oral Route: single Dose: 0.8 g Sources: Page: p.120 |
healthy, 2 n = 1 Health Status: healthy Age Group: 2 Sex: M Population Size: 1 Sources: Page: p.120 |
Status epilepticus | Disc. AE | 0.8 g single, oral Overdose Dose: 0.8 g Route: oral Route: single Dose: 0.8 g Sources: Page: p.120 |
healthy, 2 n = 1 Health Status: healthy Age Group: 2 Sex: M Population Size: 1 Sources: Page: p.120 |
Vomiting | Disc. AE | 0.8 g single, oral Overdose Dose: 0.8 g Route: oral Route: single Dose: 0.8 g Sources: Page: p.120 |
healthy, 2 n = 1 Health Status: healthy Age Group: 2 Sex: M Population Size: 1 Sources: Page: p.120 |
CNS toxicity | grade 5 Disc. AE |
3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: Page: p.757 |
unhealthy, 23 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 23 Sex: M Population Size: 1 Sources: Page: p.757 |
Ventricular tachycardia | Disc. AE | 10 g single, oral Overdose Dose: 10 g Route: oral Route: single Dose: 10 g Co-administed with:: diphenhydramine, p.o(250 mg, single) Sources: Page: p.174 |
unhealthy, 47 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 47 Sex: F Population Size: 1 Sources: Page: p.174 |
Dry mouth | 3.7% Disc. AE |
274 mg 1 times / day multiple, oral Recommended Dose: 274 mg, 1 times / day Route: oral Route: multiple Dose: 274 mg, 1 times / day Sources: Page: p.605 |
unhealthy, 53.3 n = 27 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 53.3 Sex: M+F Population Size: 27 Sources: Page: p.605 |
Serotonin syndrome | serious, 3.7% Disc. AE |
274 mg 1 times / day multiple, oral Recommended Dose: 274 mg, 1 times / day Route: oral Route: multiple Dose: 274 mg, 1 times / day Sources: Page: p.605 |
unhealthy, 53.3 n = 27 Health Status: unhealthy Condition: Multiple sclerosis Age Group: 53.3 Sex: M+F Population Size: 27 Sources: Page: p.605 |
Visual hallucinations | 4.8% DLT |
274 mg 1 times / day multiple, oral Recommended Dose: 274 mg, 1 times / day Route: oral Route: multiple Dose: 274 mg, 1 times / day Sources: |
unhealthy, 63.9 n = 63 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 63.9 Sex: M+F Population Size: 63 Sources: |
Dry mouth | 4.8% Disc. AE |
274 mg 1 times / day multiple, oral Recommended Dose: 274 mg, 1 times / day Route: oral Route: multiple Dose: 274 mg, 1 times / day Sources: |
unhealthy, 63.9 n = 63 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 63.9 Sex: M+F Population Size: 63 Sources: |
Peripheral edema | 4.8% Disc. AE |
274 mg 1 times / day multiple, oral Recommended Dose: 274 mg, 1 times / day Route: oral Route: multiple Dose: 274 mg, 1 times / day Sources: |
unhealthy, 63.9 n = 63 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 63.9 Sex: M+F Population Size: 63 Sources: |
Visual hallucinations | 7.9% Disc. AE |
274 mg 1 times / day multiple, oral Recommended Dose: 274 mg, 1 times / day Route: oral Route: multiple Dose: 274 mg, 1 times / day Sources: |
unhealthy, 63.9 n = 63 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 63.9 Sex: M+F Population Size: 63 Sources: |
Hallucinations | 15% Disc. AE |
420 mg 1 times / day multiple, oral Highest studied dose Dose: 420 mg, 1 times / day Route: oral Route: multiple Dose: 420 mg, 1 times / day Sources: Page: p.793 |
unhealthy, 66.4 n = 20 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 66.4 Sex: M+F Population Size: 20 Sources: Page: p.793 |
Balance disorder | 5% Disc. AE |
420 mg 1 times / day multiple, oral Highest studied dose Dose: 420 mg, 1 times / day Route: oral Route: multiple Dose: 420 mg, 1 times / day Sources: Page: p.793 |
unhealthy, 66.4 n = 20 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 66.4 Sex: M+F Population Size: 20 Sources: Page: p.793 |
Confusional state | 5% Disc. AE |
420 mg 1 times / day multiple, oral Highest studied dose Dose: 420 mg, 1 times / day Route: oral Route: multiple Dose: 420 mg, 1 times / day Sources: Page: p.793 |
unhealthy, 66.4 n = 20 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 66.4 Sex: M+F Population Size: 20 Sources: Page: p.793 |
Constipation | 5% Disc. AE |
420 mg 1 times / day multiple, oral Highest studied dose Dose: 420 mg, 1 times / day Route: oral Route: multiple Dose: 420 mg, 1 times / day Sources: Page: p.793 |
unhealthy, 66.4 n = 20 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 66.4 Sex: M+F Population Size: 20 Sources: Page: p.793 |
Dry mouth | 5% Disc. AE |
420 mg 1 times / day multiple, oral Highest studied dose Dose: 420 mg, 1 times / day Route: oral Route: multiple Dose: 420 mg, 1 times / day Sources: Page: p.793 |
unhealthy, 66.4 n = 20 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 66.4 Sex: M+F Population Size: 20 Sources: Page: p.793 |
Subdural hematoma | 5% Disc. AE |
420 mg 1 times / day multiple, oral Highest studied dose Dose: 420 mg, 1 times / day Route: oral Route: multiple Dose: 420 mg, 1 times / day Sources: Page: p.793 |
unhealthy, 66.4 n = 20 Health Status: unhealthy Condition: Levodopa-Induced Dyskinesia in Parkinson Disease Age Group: 66.4 Sex: M+F Population Size: 20 Sources: Page: p.793 |
Dry mouth | below serious, 4 patients | 100 mg 3 times / day steady, oral Dose: 100 mg, 3 times / day Route: oral Route: steady Dose: 100 mg, 3 times / day Sources: |
unhealthy n = 36 Health Status: unhealthy Condition: Parkinson's disease Population Size: 36 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
PubMed
Title | Date | PubMed |
---|---|---|
Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. | 1991 Dec |
|
Neurotoxicity of chlorpromazine and modulation by amantadine as a function of mouse strain. | 1991 Fall |
|
Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? | 1992 |
|
A trigger for Tourette's syndrome. | 1992 Mar |
|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. | 1992 Sep |
|
[Cortico-basal degeneration: the rare form of tau protein disease]. | 2003 |
|
Heterocyclic rimantadine analogues with antiviral activity. | 2003 Dec 1 |
|
Livedo reticularis induced by amantadine. | 2003 Sep |
|
Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin. | 2004 Aug |
|
Bitterness evaluation of medicines for pediatric use by a taste sensor. | 2004 Aug |
|
Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. | 2004 Aug |
|
Effects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary study. | 2004 Jan |
|
Motor-learning impairment by amantadine in healthy volunteers. | 2004 Jan |
|
Liquid chromatographic determination of 1-adamantanamine and 2-adamantanamine in human plasma after pre-column derivatization with o-phthalaldehyde and 1-thio-beta-D-glucose. | 2004 Jan 25 |
|
Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. | 2004 Jan 29 |
|
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. | 2004 Jul |
|
New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. | 2004 Jun |
|
Treatment of interferon non-responsive chronic hepatitis C with triple therapy with interferon, ribavirin, and amantidine can be encouraging. | 2004 Mar |
|
[Comparative study of neurophysiological effects of adamantane derivatives in the experimental parkinsonism model]. | 2004 Mar-Apr |
|
Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. | 2004 May |
|
Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults. | 2004 Nov |
|
Prevention of influenza in the general population. | 2004 Nov 9 |
|
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations. | 2004 Oct |
|
The potential anti-hBV effect of amantadine in combination with ursodeoxycholic acid and biphenyl dimethyl dicarboxylate in hepG2 2.2.15 cells. | 2005 Apr |
|
Improved neurological function after Amantadine treatment in two patients with brain injury. | 2005 Apr |
|
Site-isolated porphyrin catalysts in imprinted polymers. | 2005 Aug 19 |
|
Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. | 2005 Dec |
|
High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro. | 2005 Feb 1 |
|
Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12. | 2005 Jul |
|
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. | 2005 Jul |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. | 2005 Nov |
|
Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study. | 2005 Sep |
|
Determination of serum amantadine by liquid chromatography-tandem mass spectrometry. | 2005 Sep |
|
Glutamate receptors in neuroinflammatory demyelinating disease. | 2006 |
|
Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. | 2006 Feb |
|
A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. | 2006 Feb 14 |
|
[Cytosine demethylation in the tyrosine hydroxylase gene promoter in the hypothalamus cells of the rat brain under the action of an aminoadamantane derivative Ladasten]. | 2006 Jul |
|
The pharmacology of aminoadamantane nitrates. | 2006 Jul |
|
Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. | 2006 Jul |
|
Amantadine-induced livedo reticularis: a report of two cases. | 2006 Mar |
|
Hiccups associated with dopamine agonists in Parkinson disease. | 2006 Mar 14 |
|
Interferon signal transduction of biphenyl dimethyl dicarboxylate/amantadine and anti-HBV activity in HepG2 2.2.15. | 2006 May |
|
Simultaneous liquid chromatographic assay of amantadine and its four related compounds in phosphate-buffered saline using 4-fluoro-7-nitro-2,1,3-benzoxadiazole as a fluorescent derivatization reagent. | 2006 May |
|
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. | 2006 Nov |
|
Behavioral effects of aminoadamantane class NMDA receptor antagonists on schedule-induced alcohol and self-administration of water in mice. | 2006 Sep |
|
Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. | 2006 Sep 15 |
|
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. | 2007 Apr 16 |
|
19F NMR detection of the complex between amantadine and the receptor portion of the influenza A M2 ion channel in DPC micelles. | 2007 Jul 15 |
Sample Use Guides
Uncomplicated Influenza A Virus Illness:
Adult: 200 mg; two 100 mg capsules as a single daily dose. The daily dosage may be split into one capsule of 100 mg twice a day. In persons 65 years of age or older, the daily dosage is 100 mg.
Parkinsonism:
Adult: is 100 mg twice a day when used alone. Amantadine Hydrochloride Capsules have an onset of action usually within 48 hours. The initial dose is 100 mg daily for patients with serious associated medical illnesses or who are receiving high doses of other antiparkinson drugs. After one to several weeks at 100 mg once daily, the dose may be increased to 100 mg twice daily, if necessary.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26201988
Amantadine markedly inhibited the proliferation of HepG2 and SMMC‑7721 cells in a dose‑ and time‑dependent manner and arrested the cell cycle at the G0/G1 phase
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:15:12 GMT 2023
by
admin
on
Fri Dec 15 15:15:12 GMT 2023
|
Record UNII |
BF4C9Z1J53
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C93038
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
||
|
NDF-RT |
N0000175542
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
||
|
NCI_THESAURUS |
C38149
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
||
|
WHO-ATC |
N04BB01
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
||
|
NDF-RT |
N0000175543
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
||
|
WHO-VATC |
QN04BB01
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
||
|
LIVERTOX |
NBK547954
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
BF4C9Z1J53
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
DTXSID8022117
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
4128
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
341865
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
620
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | RxNorm | ||
|
144
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
SUB05389MIG
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
D000547
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
100000087646
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
1816
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
2618
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
768-94-5
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
2130
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
Amantadine
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
BF4C9Z1J53
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
AMANTADINE
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL660
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
3202
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
C61632
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
DB00915
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
212-201-2
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | |||
|
m1638
Created by
admin on Fri Dec 15 15:15:13 GMT 2023 , Edited by admin on Fri Dec 15 15:15:13 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
EXCRETED UNCHANGED |
Amantadine is primarily excreted unchanged in the urine, and in a study of six healthy volunteers, the ratio of amantadine renal clearance to apparent plasma clearance was 0.79 ± 0.17 (mean ± SD).
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||